OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company (“Lilly”). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications.

领先的 RNAi 疗法开发商OliX Pharmaceuticals, Inc.（KOSDAQ:226950）今天宣布与礼来公司（“礼来”）达成全球许可协议。这项合作的重点是OliX的OLX75016的开发和商业化，OLX75016是一种主要针对代谢相关脂肪性肝炎（MASH）和其他心脏代谢适应症的1期候选药物。

OliX will receive an initial payment from Lilly to complete the Phase 1 clinical trial, currently underway in Australia..

OliX将收到礼来公司的首期付款，以完成目前正在澳大利亚进行的第一阶段临床试验。。

OLX75016 derives from a robust target discovered through a genome-wide association study (GWAS), a research approach for identifying genomic variants in large populations. In preclinical studies, OliX has demonstrated the efficacy of OLX75016 in addressing both MASH and liver fibrosis, as well as other cardiometabolic indications.

OLX75016源自通过全基因组关联研究（GWAS）发现的强大目标，GWAS是一种用于鉴定大量人群中基因组变异的研究方法。在临床前研究中，OliX已证明OLX75016在解决MASH和肝纤维化以及其他心脏代谢适应症方面的功效。

OliX is currently developing OLX75016 as a novel therapeutic in treating MASH accompanied by liver fibrosis, and other cardiometabolic indications..

OliX目前正在开发OLX75016作为治疗伴有肝纤维化和其他心脏代谢适应症的MASH的新型治疗剂。。

Dong Ki Lee, Ph.D., CEO of OliX Pharmaceuticals, commented, “This collaboration with Lilly marks a significant step forward for OLX75016’s development and its potential to improve treatment outcomes for a range of metabolic conditions - MASH and other cardiometabolic indications. Partnering with an industry leader like Lilly enables us to advance innovative solutions that address medical needs with a strong focus on both efficacy and safety.

OliX Pharmaceuticals首席执行官Dong Ki Lee博士评论道：“与礼来的合作标志着OLX75016的发展迈出了重要的一步，它有可能改善一系列代谢疾病的治疗效果-糖浆和其他心脏代谢适应症。与礼来这样的行业领军者合作，使我们能够推进创新解决方案，以满足医疗需求，同时注重疗效和安全性。

Together, we aim to develop therapies that offer meaningful benefits for patients and drive progress in metabolic health.”.

我们共同致力于开发为患者提供有意义益处并推动代谢健康进步的疗法。”。

About OliX Pharmaceuticals

关于OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology.

OliX Pharmaceuticals是一家临床阶段的制药公司，通过基于其专有的RNAi技术下调致病基因的表达，开发针对多种疾病的治疗方法。该公司的核心RNAi平台不对称siRNA（asiRNA）是一种基于RNA干扰（RNAi）的独特基因沉默技术，被认为是最有效的基因沉默技术。

Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases including hypertrophic scarring, dry and wet age-related macular degeneration (AMD), and subretinal fibrosis. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases..

利用这种专有的asiRNA技术，OliX开发了细胞穿透asiRNA（cp-asiRNA），这是一种治疗性RNAi平台，可有效靶向疾病，包括肥厚性瘢痕形成，干湿性年龄相关性黄斑变性（AMD）和视网膜下纤维化。OliX还开发了另一种治疗性RNAi平台GalNAc asiRNA，用于靶向多种肝病。。